Neuroendocrinology
VIDEO: New Cushing’s, acromegaly drug data prominent at ENDO annual meeting
ATLANTA — In this video exclusive, Maria Fleseriu, MD, FACE, reviews the pituitary research presented at the annual meeting of the Endocrine Society in Atlanta.
Oral acromegaly therapy maintains efficacy for most initial responders at 62 weeks
Nearly all responders to a 26-week course of oral octreotide maintained a biochemical response and symptomatic control of acromegaly at 62 weeks, according to data from the MPOWERED trial.
Neuroendocrine tumors require individualized treatment approach
Patients with neuroendocrine tumors are at greater risk for cancer-associated death compared with death due to other causes; however, mortality rates vary according to tumor site.
Dentists, orthodontists play key role in recognizing facial manifestations of acromegaly
Dentists and orthodontists are uniquely positioned to identify the early facial manifestations of acromegaly, though new survey data suggest more awareness of the condition is needed to improve early diagnoses.
ACROSTUDY: Pegvisomant safe, effective for long-term use in acromegaly
Real-world data from the long-term ACROSTUDY show the growth hormone receptor agonist pegvisomant is safe and effective, with a low incidence of liver enzyme elevation and no increase in tumor size for most patients with acromegaly.
Oral octreotide provides sustained biochemical control in acromegaly
Adults with acromegaly who responded to treatment with an oral form of the somatostatin analogue octreotide maintained response for an additional 48 weeks with no new safety signals observed, data from an open-label extension study show.
Think beyond the CV: Ann Danoff, MD, shares advice for future endocrinologists
Ann Danoff, MD, had already established herself as a professional modern dancer performing in New York City when she picked up a friend’s copy of Cells and Organelles and saw the first parallels between movement and endocrinology.
Oral acromegaly capsule similar to injection therapy in top-line data
An oral form of the somatostatin analogue octreotide was similar to injection therapy as a long-term maintenance treatment for adults with acromegaly, according to top-line data from the MPOWERED trial.